Cargando…
Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. ME...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287237/ https://www.ncbi.nlm.nih.gov/pubmed/34799768 http://dx.doi.org/10.1007/s10620-021-07299-2 |
_version_ | 1784748208210051072 |
---|---|
author | Dong, Tien S. Jacobs, Jonathan P. Agopian, Vatche Pisegna, Joseph R. Ayoub, Walid Durazo, Francisco Enayati, Pedram Sundaram, Vinay Benhammou, Jihane N. Noureddin, Mazen Choi, Gina Lagishetty, Venu Fiehn, Oliver Goodman, Marc T. Elashoff, David Hussain, Shehnaz K. |
author_facet | Dong, Tien S. Jacobs, Jonathan P. Agopian, Vatche Pisegna, Joseph R. Ayoub, Walid Durazo, Francisco Enayati, Pedram Sundaram, Vinay Benhammou, Jihane N. Noureddin, Mazen Choi, Gina Lagishetty, Venu Fiehn, Oliver Goodman, Marc T. Elashoff, David Hussain, Shehnaz K. |
author_sort | Dong, Tien S. |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. METHODS: Patients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively. RESULTS: A total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02–54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60–13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06–9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32–20.27), methionine (HR = 9.97, 95% CI = 3.02–32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84–17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23–53.48). CONCLUSION: Alloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10620-021-07299-2. |
format | Online Article Text |
id | pubmed-9287237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-92872372022-07-17 Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis Dong, Tien S. Jacobs, Jonathan P. Agopian, Vatche Pisegna, Joseph R. Ayoub, Walid Durazo, Francisco Enayati, Pedram Sundaram, Vinay Benhammou, Jihane N. Noureddin, Mazen Choi, Gina Lagishetty, Venu Fiehn, Oliver Goodman, Marc T. Elashoff, David Hussain, Shehnaz K. Dig Dis Sci Original Article BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. METHODS: Patients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively. RESULTS: A total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02–54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60–13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06–9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32–20.27), methionine (HR = 9.97, 95% CI = 3.02–32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84–17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23–53.48). CONCLUSION: Alloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10620-021-07299-2. Springer US 2021-11-20 2022 /pmc/articles/PMC9287237/ /pubmed/34799768 http://dx.doi.org/10.1007/s10620-021-07299-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Article Dong, Tien S. Jacobs, Jonathan P. Agopian, Vatche Pisegna, Joseph R. Ayoub, Walid Durazo, Francisco Enayati, Pedram Sundaram, Vinay Benhammou, Jihane N. Noureddin, Mazen Choi, Gina Lagishetty, Venu Fiehn, Oliver Goodman, Marc T. Elashoff, David Hussain, Shehnaz K. Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis |
title | Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis |
title_full | Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis |
title_fullStr | Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis |
title_full_unstemmed | Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis |
title_short | Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis |
title_sort | duodenal microbiome and serum metabolites predict hepatocellular carcinoma in a multicenter cohort of patients with cirrhosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287237/ https://www.ncbi.nlm.nih.gov/pubmed/34799768 http://dx.doi.org/10.1007/s10620-021-07299-2 |
work_keys_str_mv | AT dongtiens duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT jacobsjonathanp duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT agopianvatche duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT pisegnajosephr duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT ayoubwalid duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT durazofrancisco duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT enayatipedram duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT sundaramvinay duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT benhammoujihanen duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT noureddinmazen duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT choigina duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT lagishettyvenu duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT fiehnoliver duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT goodmanmarct duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT elashoffdavid duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis AT hussainshehnazk duodenalmicrobiomeandserummetabolitespredicthepatocellularcarcinomainamulticentercohortofpatientswithcirrhosis |